About Eliem Therapeutics
Eliem Therapeutics is a company based in Boston (United States) founded in 2018 by Valerie Morisset and Andrew Levin. It operates as a B2B. Eliem Therapeutics has raised $171.3 million across 5 funding rounds from investors including RA Capital, ICG and LifeArc. The company has 30 employees as of December 31, 2022. Eliem Therapeutics has completed 1 acquisition, including Tenet Medicines. Eliem Therapeutics offers products and services including Budoprutug. Eliem Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Ethypharm, Zogenix and Heron Therapeutics, among others.
- Headquarter Boston, United States
- Employees 30 as on 31 Dec, 2022
- Founders Valerie Morisset, Andrew Levin
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eliem Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$171.3 M (USD)
in 5 rounds
-
Latest Funding Round
$60 M (USD), Series C
May 01, 2021
-
Investors
RA Capital
& 5 more
-
Employee Count
30
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eliem Therapeutics
Eliem Therapeutics offers a comprehensive portfolio of products and services, including Budoprutug. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Anti-CD19 antibody to deplete B cells and reduce autoantibodies.
Unlock access to complete
Unlock access to complete
Funding Insights of Eliem Therapeutics
Eliem Therapeutics has successfully raised a total of $171.3M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $60.0M
-
First Round
First Round
(04 Feb 2019)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series C - Eliem Therapeutics | Valuation |
investors |
|
| Mar, 2021 | Amount | Series C - Eliem Therapeutics | Valuation | RA Capital Management , ICG | |
| Oct, 2020 | Amount | Series B - Eliem Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eliem Therapeutics
Eliem Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, ICG and LifeArc. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
ICG is recognized as a global alternative asset manager.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eliem Therapeutics
Eliem Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tenet Medicines. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for autoimmune-driven inflammatory diseases are developed.
|
2023 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Eliem Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eliem Therapeutics Comparisons
Competitors of Eliem Therapeutics
Eliem Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Ethypharm, Zogenix and Heron Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eliem Therapeutics
Frequently Asked Questions about Eliem Therapeutics
When was Eliem Therapeutics founded?
Eliem Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is Eliem Therapeutics located?
Eliem Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Eliem Therapeutics a funded company?
Eliem Therapeutics is a funded company, having raised a total of $171.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $5M, raised on Feb 04, 2019.
How many employees does Eliem Therapeutics have?
As of Dec 31, 2022, the latest employee count at Eliem Therapeutics is 30.
What does Eliem Therapeutics do?
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.
Who are the top competitors of Eliem Therapeutics?
Eliem Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
What products or services does Eliem Therapeutics offer?
Eliem Therapeutics offers Budoprutug.
How many acquisitions has Eliem Therapeutics made?
Eliem Therapeutics has made 1 acquisition, including Tenet Medicines.
Who are Eliem Therapeutics's investors?
Eliem Therapeutics has 6 investors. Key investors include RA Capital, ICG, LifeArc, Access Biotechnology, and Samlyn Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.